| Utestående aktier | 26,533,888 shares |
| Insideraktier | 12 988 695 shares |
| Insynsägande | 48,95 % |
| Totalt antal insynspersoner | 31 |
Insider Sentiment Score
Insider sentiment score hittar de företag som köps av foretagsinsynspersoner.
Det är resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av insiderackumulation. Poängmodellen använder en kombination av nettoantalet insiders som köpt de föregående 90 dagarna, det totala antalet aktier som köpts i procent av aktiekapitalet och det totala antalet aktier som ägs av insiders. Siffran sträcker sig från 0 till 100, med högre siffror som indikerar en högre nivå av ackumulering för sina kamrater, och 50 är genomsnittet.
Uppdateringsfrekvens: Dagligen
Se Insiders Top Picks, som ger en lista över företag med högsta insiderackumulation.
Office Sentiment Score
Officersentiment Score hittar företag som köps av Corporate Officers.
Per definition Corporate Officers är Corporate Insiders, men till skillnad från vissa av de andra Insiders (10 % aktieägare och styrelseledamöter), arbetar ämbetsmän för företaget dagligen och de använder sina egna pengar när de handlar . (10 % aktieägare och styrelseledamöter är ofta fondförvaltare som förvaltar andras pengar.) Som sådan är insideraffärer som görs av tjänstemän mycket mer betydelsefulla och bör behandlas på lämpligt sätt.
Liksom Insider Sentiment Score är Officer Sentiment Score resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av officersackumulering.
Uppdateringsfrekvens: Dagligen
Se insiderns bästa val, vilket ger en lista över företag med högsta insider sentiment.
Viktiga insidernyckeltal
Denna kort visar hur företaget rankas längs olika insidernyckeltal. Procenttilrankningen visar hur detta företag jämförs med andra företag på USA-marknaden. Högre rankingar indikerar bättre situationer.
Till exempel anses det allmänt att insiderköp är en positiv indikator, så företag med mer insiderköp skulle rankas högre än företag med mindre insiderköp (eller til och med insiderförsäljning).
Procent av flytande köpta av insiders (ranking)
0.000 %( )
2569 out of 11228Procentandelen av aktier köpta av insiders är det totala antalet aktier som köpts av insiders minus det totala antalet aktier som sålts av insiders under de senaste 90 dagarna, dividerat med det totala antalet aktier och multiplicerat med 100.
Insiderhandelsdiagram
BiomX Inc. insideraffärer visas i följande diagram. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. I allmänhet är det i allmänhet olagligt för insiders att göra affärer i sina företag baserat på väsentlig, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4.
Insiderlista och lönsamhetsstatistik
Den här tabellen visar listan över kända insiders och genereras automatiskt från anmälningar som avslöjas till SEC. Förutom namnen, den senaste titeln och direktören, tjänstemannen eller ägarbeteckningen på 10 %, tillhandahåller vi de senaste avslöjade innehaven. Dessutom, när det är möjligt tillhandahåller vi insiderns historiska handelsresultat. Det historiska handelsresultatet är ett vägt genomsnitt av resultatet för faktiska köptransaktioner på den öppna marknaden som insidern gjort. För mer information om hur detta beräknas, titta på detta YouTube-webinarium.
See our leaderboard of most profitable insider traders.
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
| Gbolahan Amusa Director - [D] | 262 871 | 26 287 | |
| Merav Bassan Chief Development Officer - [O] | 79 597 | 79 597 | |
| Uri Ben-Or | 0 | ||
| Yaron Breski | 16 000 | ||
|
Chardan Investments, LLC
10% Owner -
|
3 940 000 | 3 940 000 | |
|
Erez Chimovits
10% Owner -
|
2 313 489 | 1 377 365 | |
|
Fibrosis Foundation Cystic
10% Owner -
|
1 787 758 | 1 787 758 | |
| James E Flynn Director - [D] | 1 247 054 | 1 247 054 | |
| Jonas Grossman Director - [D] | 372 717 | 37 272 | |
| Richard Giroux Director - [D] | 15 000 | 15 000 |
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
| Elliot Gnedy Director - [D] | 15 000 | 15 000 | |
| Russell Greig Director - [D] | 3 750 | 375 | |
| George Kaufman | 0 | ||
| Eric Kusseluk Director - [D] | 15 000 | 15 000 | |
|
MMCAP International Inc. SPC
10% Owner -
|
3 400 000 | 3 400 000 | |
| Alan Charles Moses Director - [D] | 5 000 | 500 | |
|
OrbiMed Israel BioFund GP Limited Partnership
10% Owner -
|
13 773 653 | 1 377 365 | |
|
OrbiMed Israel GP Ltd.
10% Owner -
|
2 813 489 | 1 377 365 | |
| Assaf Oron Chief Business Officer - [O] | 25 804 | 25 804 | |
|
Kerry Propper
10% Owner -
|
0 | 0 |
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
| Sailaja Puttagunta | 67 500 | ||
| Yehuda Michael Rice Director - [D] | 15 000 | 15 000 | |
| Matthew Rossen Director - [D] | 15 000 | 15 000 | |
| Paul J Sekhri Director - [D] | 12 500 | 1 250 | |
| Jonathan Eitan Solomon Chief Executive Officer, Director - [D] [O] | 126 748 | 126 748 | |
| Lynne Marie Sullivan Director - [D] | 12 500 | 1 250 | |
|
Pharmaceutical Co Ltd Takeda
10% Owner -
|
4 941 870 | 494 187 | |
| Chidozie Ugwumba - | 2 997 025 | 299 702 | |
|
Thomas Layton Walton
10% Owner -
|
0 | 0 | |
| Marina Wolfson Chief Financial Officer - [O] | 68 545 | 68 545 | |
| Robbie Woodman | 0 |
Report errors via our new Insider Auditing Tool
Track Records av insiderköp - Kortsiktig vinstanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i PHGE / BiomX Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste köpen på öppna marknaden som inte var en del av en automatisk handelsplan.
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Track Records av insiderförsäljning - Kortsiktig förlustanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i PHGE / BiomX Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste försäljningarna på öppna marknaden som inte var en del av en automatisk handelsplan.
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Transaktionshistorik
Klicka på länkikonen för att se hela transaktionshistoriken. Transaktioner som rapporteras som en del av en automatisk handelsplan 10b5-1 kommer att ha ett X i kolumnen markerad 10b-5.
| Fil datum |
Handel datum |
Schema | Insider | Ticker | Värdepappertitel | Kod | Direkta | Utövningspris | Enhet pris |
Enheter ändrad |
Värde ändrad (1K) |
Kvarvarande Optioner |
Kvarvarande Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-21 | 2025-04-14 | 4/A | Bassan Merav | PHGE | Common Stock | D | 79 597 | 79 597 | ||||||
| 2025-04-21 | 2025-04-14 | 4/A | Solomon Jonathan Eitan | PHGE | Common Stock | D | 126 748 | 126 748 | ||||||
| 2025-04-21 | 2025-04-14 | 4/A | Wolfson Marina | PHGE | Common Stock | D | 68 545 | 68 545 | ||||||
| 2025-04-18 | 2025-04-14 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock | D | 126 748 | 126 748 | ||||||
| 2025-04-18 | 2025-04-14 | 4 | Bassan Merav | PHGE | Common Stock | D | 79 597 | 79 597 | ||||||
| 2025-04-18 | 2025-04-14 | 4 | Wolfson Marina | PHGE | Common Stock | D | 68 545 | 68 545 | ||||||
| 2025-03-04 | 2024-07-15 | 5 | Cystic Fibrosis Foundation | PHGE | Common Stock, par value $0.0001 per share | D | 854 700 | 1 787 758 | ||||||
| 2025-03-03 | 2025-02-27 | 4 | Flynn James E Through Deerfield Healthcare Innovations Fund II, L.P. | PHGE | Common Stock | I | 0,9306 | 353 249 | 329 | 1 247 054 | ||||
| 2025-03-03 | 2025-02-27 | 4 | Flynn James E Through Deerfield Private Design Fund V, L.P. | PHGE | Common Stock | I | 0,9306 | 353 249 | 329 | 1 247 054 | ||||
| 2024-09-18 | 2024-09-16 | 4 | Bassan Merav | PHGE | Common Stock | D | 31 749 | 31 749 | ||||||
| 2024-09-18 | 2024-09-16 | 4 | Oron Assaf | PHGE | Common Stock | D | 25 804 | 25 804 | ||||||
| 2024-09-18 | 2024-09-16 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock | D | 50 556 | 53 056 | ||||||
| 2024-07-17 | 2024-07-15 | 4 | Flynn James E Through Deerfield Private Design Fund V, L.P. | PHGE | Common Stock | I | 5 883 000 | 8 938 049 | ||||||
| 2024-07-17 | 2024-07-15 | 4 | Flynn James E Through Deerfield Healthcare Innovations Fund II, L.P. | PHGE | Common Stock | I | 5 883 000 | 8 938 049 | ||||||
| 2024-05-20 | 2024-05-15 | 4 | OrbiMed Israel BioFund GP Limited Partnership See footnotes | PHGE | Common Stock | I | 0,3812 | −24 344 | −9 | 13 773 653 | ||||
| 2024-05-20 | 2024-05-15 | 4 | OrbiMed Israel BioFund GP Limited Partnership See footnotes | PHGE | Common Stock | I | 0,2440 | 9 280 408 | 2 264 | 13 797 997 | ||||
| 2024-05-17 | 2024-05-15 | 4 | Cystic Fibrosis Foundation | PHGE | Common Stock, par value $0.0001 per share | D | 0,0010 | 4 778 265 | 5 | 9 330 580 | ||||
| 2024-03-26 | 3 | Cystic Fibrosis Foundation | PHGE | Common Stock, par value $0.0001 per share | D | 4 552 315 | ||||||||
| 2024-03-19 | 2024-03-15 | 4 | Flynn James E Through Deerfield Healthcare Innovations Fund II, L.P. | PHGE | Common Stock | I | 3 055 049 | 3 055 049 | ||||||
| 2024-03-19 | 2024-03-15 | 4 | Flynn James E Through Deerfield Private Design Fund V, L.P. | PHGE | Common Stock | I | 3 055 049 | 3 055 049 | ||||||
| 2023-12-01 | 2023-11-29 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,3400 | −2 056 | −1 | 0 | ||||
| 2023-12-01 | 2023-11-29 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,3500 | −3 414 | −1 | 2 056 | ||||
| 2023-12-01 | 2023-11-29 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,4000 | −5 444 | −2 | 5 470 | ||||
| 2023-05-24 | 2023-05-22 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,2731 | 3 192 | 1 | 10 914 | ||||
| 2023-05-22 | 2023-05-19 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,2809 | 6 521 | 2 | 7 722 | ||||
| 2023-05-22 | 2023-05-18 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,2727 | 1 201 | 0 | 1 201 | ||||
| 2023-03-17 | 2023-02-27 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock | I | 0,2450 | 348 000 | 85 | 3 161 489 | ||||
| 2022-11-14 | 2022-11-04 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3780 | −1 501 | −1 | 2 997 025 | ||||
| 2022-11-14 | 2022-11-03 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3660 | −2 000 | −1 | 2 998 526 | ||||
| 2022-11-14 | 2022-11-02 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3590 | −2 416 | −1 | 3 000 526 | ||||
| 2022-11-14 | 2022-11-01 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3640 | −1 300 | −0 | 3 002 942 | ||||
| 2022-11-14 | 2022-10-31 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3710 | −3 300 | −1 | 3 004 242 | ||||
| 2022-11-14 | 2022-10-28 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3560 | −1 526 | −1 | 3 007 542 | ||||
| 2022-11-14 | 2022-10-27 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3640 | −1 505 | −1 | 3 009 068 | ||||
| 2022-11-14 | 2022-10-26 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3460 | −12 500 | −4 | 3 010 573 | ||||
| 2022-11-14 | 2022-10-25 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3650 | −3 072 | −1 | 3 023 073 | ||||
| 2022-11-14 | 2022-10-24 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3490 | −5 900 | −2 | 3 026 145 | ||||
| 2022-11-14 | 2022-10-21 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3700 | −5 400 | −2 | 3 032 045 | ||||
| 2022-11-14 | 2022-10-20 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3740 | −6 636 | −2 | 3 037 445 | ||||
| 2022-11-14 | 2022-10-19 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3670 | −4 501 | −2 | 3 044 081 | ||||
| 2022-11-14 | 2022-10-18 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3460 | −15 300 | −5 | 3 048 582 | ||||
| 2022-11-14 | 2022-10-17 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3350 | −8 098 | −3 | 3 063 882 | ||||
| 2022-11-14 | 2022-10-14 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3310 | −3 420 | −1 | 3 071 980 | ||||
| 2022-11-14 | 2022-10-13 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3300 | −11 314 | −4 | 3 075 400 | ||||
| 2022-11-14 | 2022-10-12 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3330 | −9 700 | −3 | 3 086 714 | ||||
| 2022-11-14 | 2022-10-11 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3320 | −5 988 | −2 | 3 096 414 | ||||
| 2022-11-14 | 2022-10-10 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3260 | −10 043 | −3 | 3 102 402 | ||||
| 2022-11-14 | 2022-10-07 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3580 | −24 708 | −9 | 3 112 445 | ||||
| 2022-11-14 | 2022-10-06 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4440 | −25 098 | −11 | 3 137 153 | ||||
| 2022-11-14 | 2022-10-05 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4350 | −46 785 | −20 | 3 162 251 | ||||
| 2022-11-14 | 2022-10-04 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3440 | −19 200 | −7 | 3 209 036 | ||||
| 2022-11-14 | 2022-10-03 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3300 | −15 022 | −5 | 3 228 236 | ||||
| 2022-11-14 | 2022-09-30 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3560 | −8 662 | −3 | 3 243 258 | ||||
| 2022-11-14 | 2022-09-29 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3490 | −3 300 | −1 | 3 251 920 | ||||
| 2022-11-14 | 2022-09-28 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3330 | −15 649 | −5 | 3 255 220 | ||||
| 2022-11-14 | 2022-09-27 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3310 | −4 866 | −2 | 3 270 869 | ||||
| 2022-11-14 | 2022-09-26 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3550 | −17 528 | −6 | 3 275 735 | ||||
| 2022-11-14 | 2022-09-23 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3740 | −5 306 | −2 | 3 293 263 | ||||
| 2022-11-14 | 2022-09-22 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4130 | −17 388 | −7 | 3 298 569 | ||||
| 2022-11-14 | 2022-09-21 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4270 | −5 574 | −2 | 3 315 957 | ||||
| 2022-11-14 | 2022-09-20 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4510 | −10 626 | −5 | 3 321 531 | ||||
| 2022-11-14 | 2022-09-19 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4850 | −13 870 | −7 | 3 332 157 | ||||
| 2022-11-14 | 2022-09-16 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5130 | −3 200 | −2 | 3 346 027 | ||||
| 2022-11-14 | 2022-09-15 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5310 | −3 900 | −2 | 3 349 227 | ||||
| 2022-11-14 | 2022-09-14 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5230 | −2 301 | −1 | 3 353 127 | ||||
| 2022-11-14 | 2022-09-13 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5250 | −2 201 | −1 | 3 335 428 | ||||
| 2022-11-14 | 2022-09-12 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5410 | −1 700 | −1 | 3 357 629 | ||||
| 2022-11-14 | 2022-09-09 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5180 | −13 219 | −7 | 3 359 329 | ||||
| 2022-11-14 | 2022-09-08 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5220 | −4 592 | −2 | 3 372 548 | ||||
| 2022-11-14 | 2022-09-07 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5280 | −8 846 | −5 | 3 377 140 | ||||
| 2022-11-14 | 2022-09-06 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5450 | −6 403 | −3 | 3 385 986 | ||||
| 2022-11-14 | 2022-09-02 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5460 | −2 001 | −1 | 3 392 389 | ||||
| 2022-11-14 | 2022-09-01 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5460 | −8 297 | −5 | 3 394 390 | ||||
| 2022-11-14 | 2022-08-31 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5490 | −4 540 | −2 | 3 402 687 | ||||
| 2022-11-14 | 2022-08-30 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5660 | −13 487 | −8 | 3 407 227 | ||||
| 2022-11-14 | 2022-08-29 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5710 | −11 533 | −7 | 3 420 714 | ||||
| 2022-11-14 | 2022-08-26 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6160 | −60 628 | −37 | 3 432 247 | ||||
| 2022-11-14 | 2022-08-25 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,7180 | −26 945 | −19 | 3 492 875 | ||||
| 2022-11-14 | 2022-08-24 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6520 | −8 665 | −6 | 3 519 820 | ||||
| 2022-11-14 | 2022-08-23 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6380 | −5 900 | −4 | 3 528 485 | ||||
| 2022-11-14 | 2022-08-22 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6570 | −5 000 | −3 | 3 534 385 | ||||
| 2022-11-14 | 2022-08-19 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6390 | −14 600 | −9 | 3 539 385 | ||||
| 2022-11-14 | 2022-08-18 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6830 | −7 764 | −5 | 3 553 985 | ||||
| 2022-11-14 | 2022-08-17 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6880 | −21 335 | −15 | 3 561 749 | ||||
| 2022-11-14 | 2022-08-16 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,7290 | −8 563 | −6 | 3 583 084 | ||||
| 2022-11-14 | 2022-08-15 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,7470 | −7 200 | −5 | 3 591 647 | ||||
| 2022-11-14 | 2022-08-12 | 4 | Ugwumba Chidozie By Symbiosis, LLC | PHGE | Common Stock | I | 0,7340 | −11 406 | −8 | 3 598 847 | ||||
| 2022-11-14 | 2022-08-11 | 4 | Ugwumba Chidozie By Symbiosis, LLC | PHGE | Common Stock | I | 0,7440 | −9 824 | −7 | 3 610 253 | ||||
| 2022-11-14 | 2022-08-10 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,7400 | −17 769 | −13 | 3 620 077 | ||||
| 2022-03-31 | 2022-03-29 | 4 | GROSSMAN JONAS | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 20 500 | 20 500 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Sullivan Lynne Marie | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 20 500 | 20 500 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Amusa Gbolahan | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 20 500 | 20 500 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Greig Russell | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 41 000 | 41 000 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Wolfson Marina | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 50 000 | 50 000 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 205 000 | 205 000 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Bassan Merav | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 100 000 | 100 000 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Moses Alan Charles | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 20 500 | 20 500 | |||||
| 2022-02-14 | 2021-12-31 | 4 | Walton Thomas Layton By SymBiosis, LLC | PHGE | Warrants to purchase Common Stock | I | 5,00 | −1 875 000 | 0 | |||||
| 2022-02-14 | 2021-12-31 | 4 | Walton Thomas Layton By SymBiosis, LLC | PHGE | Common Stock, $0.0001 par value | I | −3 637 846 | 0 | ||||||
| 2022-02-14 | 3 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 3 637 846 | ||||||||
| 2021-08-17 | 2021-07-26 | 4/A | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 37 500 | 372 717 | ||||||
| 2021-08-17 | 2020-07-26 | 4/A | GROSSMAN JONAS | PHGE | Warrants to purchase Common Stock | D | 5,00 | 28 125 | 28 125 | |||||
| 2021-08-09 | 3 | Walton Thomas Layton By SymBiosis, LLC | PHGE | Common Stock, $0.0001 par value | I | 3 637 846 | ||||||||
| 2021-07-30 | 2021-07-28 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Warrants (Right to Buy) | I | 5,00 | 375 000 | 375 000 | |||||
| 2021-07-30 | 2021-07-28 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.0001 par value | I | 500 000 | 2 813 489 | ||||||
| 2021-07-30 | 2021-07-28 | 4 | Wolfson Marina | PHGE | Common Stock Warrant | D | 5,00 | 2 813 | 2 813 | |||||
| 2021-07-30 | 2021-07-28 | 4 | Wolfson Marina | PHGE | Common Stock | D | 4,0000 | 3 750 | 15 | 3 750 | ||||
| 2021-07-30 | 2021-07-28 | 4 | Sullivan Lynne Marie | PHGE | Common Stock Warrant | D | 5,00 | 9 375 | 9 375 | |||||
| 2021-07-30 | 2021-07-28 | 4 | Sullivan Lynne Marie | PHGE | Common Stock | D | 4,0000 | 12 500 | 50 | 12 500 | ||||
| 2021-07-30 | 2021-07-28 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock Warrant | D | 5,00 | 18 750 | 18 750 | |||||
| 2021-07-30 | 2021-07-28 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock | D | 4,0000 | 25 000 | 100 | 25 000 | ||||
| 2021-07-30 | 2021-07-28 | 4 | SEKHRI PAUL J | PHGE | Common Stock Warrant | D | 5,00 | 9 375 | 9 375 | |||||
| 2021-07-30 | 2021-07-28 | 4 | SEKHRI PAUL J | PHGE | Common Stock | D | 4,0000 | 12 500 | 50 | 12 500 | ||||
| 2021-07-30 | 2021-07-28 | 4 | Greig Russell | PHGE | Common Stock Warrant | I | 5,00 | 2 813 | 2 813 | |||||
| 2021-07-30 | 2021-07-28 | 4 | Greig Russell | PHGE | Common Stock | I | 4,0000 | 3 750 | 15 | 3 750 | ||||
| 2021-07-30 | 2021-07-28 | 4 | Moses Alan Charles | PHGE | Common Stock Warrant | D | 5,00 | 3 750 | 3 750 | |||||
| 2021-07-30 | 2021-07-28 | 4 | Moses Alan Charles | PHGE | Common Stock | D | 4,0000 | 5 000 | 20 | 5 000 | ||||
| 2021-07-28 | 2021-07-26 | 4 | GROSSMAN JONAS | PHGE | Warrants to purchase Common Stock | D | 5,00 | 28 125 | 28 125 | |||||
| 2021-07-28 | 2021-07-26 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 37 500 | 372 217 | ||||||
| 2021-07-28 | 2021-07-26 | 4 | Amusa Gbolahan | PHGE | Warrants to purchase Common Stock | D | 5,00 | 18 750 | 18 750 | |||||
| 2021-07-28 | 2021-07-26 | 4 | Amusa Gbolahan | PHGE | Common Stock, par value $0.0001 | D | 25 000 | 262 871 | ||||||
| 2021-04-01 | 2021-03-30 | 4 | Puttagunta Sailaja | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 71 250 | 71 250 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Greig Russell | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 30 400 | 30 400 | |||||
| 2021-04-01 | 2021-03-30 | 4 | SEKHRI PAUL J | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 15 200 | 15 200 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Oron Assaf | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 33 250 | 33 250 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Moses Alan Charles | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 15 200 | 15 200 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Bassan Merav | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 47 500 | 47 500 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Wolfson Marina | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 33 250 | 33 250 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Sullivan Lynne Marie | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 15 200 | 15 200 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 152 000 | 152 000 | |||||
| 2021-04-01 | 2021-03-30 | 4 | GROSSMAN JONAS | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 15 200 | 15 200 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Amusa Gbolahan | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 15 200 | 15 200 | |||||
| 2020-10-05 | 2020-10-02 | 4 | SEKHRI PAUL J | PHGE | Common Stock Options - Right to Buy | D | 6,44 | 16 000 | 16 000 | |||||
| 2020-10-05 | 2020-10-02 | 4 | Moses Alan Charles | PHGE | Common Stock Options - Right to Buy | D | 6,44 | 16 000 | 16 000 | |||||
| 2020-07-27 | 2020-07-13 | 4 | Amusa Gbolahan | PHGE | Warrants to purchase Common Stock | D | 11,50 | 276 190 | 276 190 | |||||
| 2020-07-27 | 2020-07-13 | 4 | Amusa Gbolahan | PHGE | Common Stock, par value $0.0001 | D | 95 148 | 237 871 | ||||||
| 2020-07-22 | 2020-07-13 | 4 | PROPPER KERRY By Mountain Wood, LLC | PHGE | Warrants to purchase Common Stock | I | 11,50 | −2 900 000 | 0 | |||||
| 2020-07-22 | 2020-07-13 | 4 | PROPPER KERRY | PHGE | Warrants to purchase Common Stock | D | 11,50 | 631 786 | 631 786 | |||||
| 2020-07-22 | 2020-07-13 | 4 | PROPPER KERRY By Mountain Wood, LLC | PHGE | Common Stock, par value $0.0001 | I | −999 058 | 0 | ||||||
| 2020-07-22 | 2020-07-13 | 4 | PROPPER KERRY | PHGE | Common Stock, par value $0.0001 | D | 217 652 | 260 771 | ||||||
| 2020-07-22 | 2020-07-13 | 4 | GROSSMAN JONAS | PHGE | Warrants to purchase Common Stock | D | 11,50 | 666 310 | 716 439 | |||||
| 2020-07-22 | 2020-07-13 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 229 545 | 335 217 | ||||||
| 2020-07-22 | 2020-06-18 | 4 | GROSSMAN JONAS By Ravenna LLC | PHGE | Common Stock, par value $0.0001 | I | −45 275 | 0 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | PROPPER KERRY By Mountain Wood, LLC | PHGE | Common Stock, par value $0.0001 | I | 999 058 | 999 058 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | PROPPER KERRY | PHGE | Common Stock, par value $0.0001 | D | 43 119 | 43 119 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | Amusa Gbolahan | PHGE | Common Stock, par value $0.0001 | D | 142 723 | 142 723 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | GROSSMAN JONAS By Ravenna LLC | PHGE | Common Stock, par value $0.0001 | I | 42 275 | 45 275 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | GROSSMAN JONAS By Chardan Investments, LLC | PHGE | Common Stock, par value $0.0001 | I | −1 707 500 | 0 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 99 172 | 105 672 | ||||||
| 2020-03-27 | 2020-03-25 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 144 000 | 144 000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | GROSSMAN JONAS | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 16 000 | 16 000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Chimovits Erez | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 16 000 | 16 000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Amusa Gbolahan | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 16 000 | 16 000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Oron Assaf | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 31 500 | 31 500 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Sullivan Lynne Marie | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 16 000 | 16 000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Breski Yaron | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 16 000 | 16 000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Wolfson Marina | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 36 000 | 36 000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Puttagunta Sailaja | PHGE | Common Stock Options - Right to Buy | I | 6,21 | 67 500 | 67 500 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Greig Russell | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 32 000 | 32 000 | |||||
| 2019-12-30 | 2019-12-20 | 4 | GROSSMAN JONAS | PHGE | Warrants | I | 11,50 | −2 900 000 | 0 | |||||
| 2019-12-20 | 2019-12-19 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9000 | 3 500 | 31 | 2 313 489 | ||||
| 2019-12-20 | 2019-12-18 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9300 | 500 | 4 | 2 309 989 | ||||
| 2019-12-20 | 2019-12-19 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9000 | 3 500 | 31 | 2 313 489 | ||||
| 2019-12-20 | 2019-12-18 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9300 | 500 | 4 | 2 309 989 | ||||
| 2019-12-12 | 2019-12-11 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9200 | 5 400 | 48 | 2 309 489 | ||||
| 2019-12-12 | 2019-12-10 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,7500 | 3 400 | 30 | 2 304 089 | ||||
| 2019-12-12 | 2019-12-11 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9200 | 5 400 | 48 | 2 309 489 | ||||
| 2019-12-12 | 2019-12-10 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,7500 | 3 400 | 30 | 2 304 089 | ||||
| 2019-12-09 | 2019-12-09 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,6800 | 6 000 | 52 | 2 300 689 | ||||
| 2019-12-09 | 2019-12-06 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,0000 | 800 | 6 | 2 294 689 | ||||
| 2019-12-09 | 2019-12-05 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 7,9900 | 3 400 | 27 | 2 293 889 | ||||
| 2019-12-09 | 2019-12-09 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,6800 | 6 000 | 52 | 2 300 689 | ||||
| 2019-12-09 | 2019-12-06 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,0000 | 800 | 6 | 2 294 689 | ||||
| 2019-12-09 | 2019-12-05 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 7,9900 | 3 400 | 27 | 2 293 889 | ||||
| 2019-11-20 | 2019-11-20 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 8,0040 | 1 400 | 11 | 6 500 | ||||
| 2019-11-20 | 2019-11-19 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 7,5730 | 4 100 | 31 | 5 100 | ||||
| 2019-11-20 | 2019-11-18 | 4 | GROSSMAN JONAS | PHGE | Warrants | D | 11,50 | 0,5990 | 50 129 | 30 | 50 129 | |||
| 2019-11-20 | 2019-11-18 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 6,9890 | 1 000 | 7 | 1 000 | ||||
| 2019-11-07 | 3 | Chimovits Erez See Footnotes | PHGE | Common Stock | I | 4 580 980 | ||||||||
| 2019-11-07 | 3 | Chimovits Erez See Footnotes | PHGE | Common Stock | I | 4 580 980 | ||||||||
| 2019-11-07 | 3 | Chimovits Erez See Footnotes | PHGE | Common Stock | I | 4 580 980 | ||||||||
| 2019-11-07 | 3 | OrbiMed Israel GP Ltd. See Footnotes | PHGE | Common Stock | I | 4 580 980 | ||||||||
| 2019-11-07 | 3 | OrbiMed Israel GP Ltd. See Footnotes | PHGE | Common Stock | I | 4 580 980 | ||||||||
| 2019-11-07 | 3 | OrbiMed Israel GP Ltd. See Footnotes | PHGE | Common Stock | I | 4 580 980 | ||||||||
| 2019-11-07 | 3 | OrbiMed Israel GP Ltd. See Footnotes | PHGE | Common Stock | I | 4 580 980 | ||||||||
| 2019-11-05 | 3 | Takeda Ventures, Inc. | PHGE | Common Stock | I | 4 941 870 | ||||||||
| 2019-11-05 | 3 | Takeda Ventures, Inc. | PHGE | Common Stock | I | 4 941 870 | ||||||||
| 2019-11-05 | 3 | Takeda Ventures, Inc. | PHGE | Common Stock | I | 4 941 870 | ||||||||
| 2019-11-05 | 3 | Takeda Ventures, Inc. | PHGE | Common Stock | I | 4 941 870 | ||||||||
| 2019-09-19 | 3 | MMCAP International Inc. SPC | CHAC | Common Stock | D | 3 400 000 | ||||||||
| 2019-09-19 | 3 | MMCAP International Inc. SPC | CHAC | Common Stock | D | 3 400 000 | ||||||||
| 2019-09-19 | 3 | MMCAP International Inc. SPC | CHAC | Common Stock | D | 3 400 000 | ||||||||
| 2018-12-21 | 3 | Gnedy Elliot | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-21 | 3 | Gnedy Elliot | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-21 | 3 | Gnedy Elliot | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-19 | 2018-12-18 | 4 | GROSSMAN JONAS | CHAC | Warrants | I | 11,50 | 0,4000 | 2 900 000 | 1 160 | 2 900 000 | |||
| 2018-12-14 | 3 | Kusseluk Eric | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-14 | 3 | Kusseluk Eric | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-14 | 3 | Kusseluk Eric | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-14 | 3 | GROSSMAN JONAS | CHAC | Common Stock, par value $0.0001 | I | 3 940 000 | ||||||||
| 2018-12-14 | 3 | GROSSMAN JONAS | CHAC | Common Stock, par value $0.0001 | I | 3 940 000 | ||||||||
| 2018-12-14 | 3 | GROSSMAN JONAS | CHAC | Common Stock, par value $0.0001 | I | 3 940 000 | ||||||||
| 2018-12-14 | 3 | Rossen Matthew | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-14 | 3 | Rossen Matthew | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-14 | 3 | Rossen Matthew | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-14 | 3 | RICE YEHUDA MICHAEL | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-14 | 3 | RICE YEHUDA MICHAEL | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-14 | 3 | RICE YEHUDA MICHAEL | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-14 | 3 | Chardan Investments, LLC | CHAC | Common Stock, par value $0.0001 | D | 3 940 000 | ||||||||
| 2018-12-14 | 3 | Chardan Investments, LLC | CHAC | Common Stock, par value $0.0001 | D | 3 940 000 | ||||||||
| 2018-12-14 | 3 | Chardan Investments, LLC | CHAC | Common Stock, par value $0.0001 | D | 3 940 000 | ||||||||
| 2018-12-14 | 3 | Giroux Richard | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-14 | 3 | Giroux Richard | CHAC | Common Stock, par value $0.0001 | D | 15 000 | ||||||||
| 2018-12-14 | 3 | Giroux Richard | CHAC | Common Stock, par value $0.0001 | D | 15 000 |
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)
